Physician profile
Russell E Ditzler
NPI 1053378588
$9,616.97
in general payments reported to CMS, 2019-2025
52 companies · $1,702 in 2025
The $1,702 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,891 · 2020: $320 · 2021: $490 · 2022: $1,414 · 2023: $1,953 · 2024: $1,848 · 2025: $1,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,470 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,469.70 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,472.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,116.12 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $881.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $846.96 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $826.76 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $542.82 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $541.28 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $483.79 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.15 | 2019-2025 | Jardiance |
| Jazz Pharmaceuticals INC. | $204.93 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $183.68 | 2023-2025 | Voquezna |
| Astellas Pharma US INC | $175.97 | 2019-2025 | Veozah |
| Daiichi Sankyo INC. | $158.52 | 2019-2025 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.25 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $136.14 | 2019 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Ditzler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.